The Ozempic Era: Disrupting Medtech and Bariatric Surgery
While it might seem unlikely, the stage for this disruption was set during an episode of The Dr. Oz Show. Semaglutide, Novo Nordisk’s GLP-1 receptor agonist, was initially developed for diabetes management and later explored for its potential to treat Alzheimer’s and dementia. However. This blog is originally published here: https://www.lifesciencemarketr....esearch.com/insights
Comment
Share
